QDEL
QuidelOrtho Corporation NASDAQ Listed Feb 1, 1991$10.77
Mkt Cap $732.9M
52w Low $10.21
1.9% of range
52w High $38.99
50d MA $16.09
200d MA $24.58
P/E (TTM)
-0.8x
EV/EBITDA
-9.5x
P/B
0.5x
Debt/Equity
1.5x
ROE
-58.9%
P/FCF
-23.9x
RSI (14)
—
ATR (14)
—
Beta
0.92
50d MA
$16.09
200d MA
$24.58
Avg Volume
2.0M
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
9975 Summers Ridge Road · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 0.37 | -0.04 | -110.8% | 11.66 | -4.3% | -6.0% | -7.6% | — | — | — | — |
| Feb 11, 2026 | AMC | 0.43 | 0.46 | +7.0% | 28.80 | -7.4% | -17.6% | -18.1% | -19.7% | -16.1% | -18.0% | — |
| Nov 5, 2025 | AMC | 0.51 | 0.80 | +56.9% | 27.37 | -3.3% | -22.3% | -25.6% | -27.9% | -20.0% | -17.5% | — |
| Aug 5, 2025 | AMC | 0.56 | 0.12 | -78.6% | 23.68 | +15.1% | -1.0% | +3.0% | +1.0% | -0.2% | +6.4% | — |
| May 7, 2025 | AMC | 0.58 | 0.74 | +27.6% | 25.85 | +10.9% | +41.0% | +40.6% | +44.8% | +37.4% | +29.8% | — |
| Feb 12, 2025 | AMC | 0.55 | 0.63 | +14.5% | 39.94 | +9.7% | +4.3% | +1.6% | +3.9% | +4.9% | +2.7% | — |
| Nov 7, 2024 | AMC | 0.31 | 0.85 | +174.2% | 38.85 | +7.5% | +12.6% | +10.6% | +5.9% | +3.0% | +0.3% | — |
| Jul 31, 2024 | AMC | -0.21 | -0.07 | +66.7% | 39.29 | +6.5% | +6.9% | +6.9% | +3.3% | +2.0% | +0.8% | — |
| May 8, 2024 | AMC | 0.43 | 0.44 | +2.3% | 42.68 | -0.1% | +2.2% | -0.2% | -1.3% | +3.5% | +5.3% | — |
| Feb 13, 2024 | AMC | 2.02 | 1.17 | -42.1% | 66.77 | -30.7% | -32.2% | -34.1% | -37.5% | -30.2% | -25.9% | — |
| Nov 1, 2023 | AMC | 0.45 | 0.90 | +100.0% | 60.50 | +2.6% | +3.7% | +6.2% | +3.9% | +1.8% | -0.3% | — |
| Aug 8, 2023 | AMC | 0.25 | 0.26 | +4.0% | 82.26 | -3.0% | -7.3% | -5.9% | -5.3% | -7.2% | -9.2% | — |
| May 3, 2023 | AMC | 1.40 | 1.80 | +28.6% | 93.23 | -0.6% | -6.5% | -5.0% | -5.3% | -7.7% | -6.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7 | Jefferies | Downgrade | Buy → Hold | $12 | $10.96 | $10.81 | -1.4% | -1.7% | — | — | — | — |
| Apr 10 | UBS | Maintains | Neutral → Neutral | — | $14.15 | $14.08 | -0.5% | -2.1% | +13.6% | +22.4% | +23.6% | -10.3% |
| Feb 12 | Citigroup | Maintains | Neutral → Neutral | — | $28.80 | $26.68 | -7.4% | -17.6% | -18.1% | -19.7% | -16.1% | -18.0% |
| Jan 21 | UBS | Maintains | Neutral → Neutral | — | $32.73 | $32.20 | -1.6% | -10.1% | -6.6% | -14.2% | -12.4% | -16.7% |
| Nov 7 | JP Morgan | Maintains | Underweight → Underweight | — | $21.26 | $21.01 | -1.2% | -4.3% | -7.2% | +3.0% | +6.3% | +4.3% |
| Nov 6 | UBS | Maintains | Neutral → Neutral | — | $27.37 | $26.48 | -3.3% | -22.3% | -25.6% | -27.9% | -20.0% | -17.5% |
| Oct 7 | Citigroup | Downgrade | Buy → Neutral | — | $29.60 | $28.45 | -3.9% | -6.4% | -5.9% | -5.2% | -10.9% | -11.1% |
| Aug 7 | UBS | Maintains | Neutral → Neutral | — | $23.44 | $23.44 | +0.0% | +4.1% | +2.0% | +0.9% | +7.5% | +15.5% |
| Aug 6 | Citigroup | Maintains | Buy → Buy | — | $23.68 | $27.26 | +15.1% | -1.0% | +3.0% | +1.0% | -0.2% | +6.4% |
| May 8 | Jefferies | Upgrade | Hold → Buy | — | $25.85 | $28.66 | +10.9% | +41.0% | +40.6% | +44.8% | +37.4% | +29.8% |
| May 8 | UBS | Maintains | Neutral → Neutral | — | $25.85 | $28.66 | +10.9% | +41.0% | +40.6% | +44.8% | +37.4% | +29.8% |
| Apr 21 | JP Morgan | Maintains | Underweight → Underweight | — | $25.17 | $24.74 | -1.7% | -2.4% | -2.8% | +2.2% | +10.4% | +11.6% |
| Feb 13 | RBC Capital | Maintains | Outperform → Outperform | — | $39.94 | $43.80 | +9.7% | +4.3% | +1.6% | +3.9% | +4.9% | +2.7% |
| Feb 13 | UBS | Maintains | Neutral → Neutral | — | $39.94 | $43.80 | +9.7% | +4.3% | +1.6% | +3.9% | +4.9% | +2.7% |
| Dec 11 | Citigroup | Upgrade | Neutral → Buy | — | $38.50 | $39.65 | +3.0% | +7.8% | +8.1% | +7.4% | +13.9% | +11.8% |
| Aug 16 | RBC Capital | Maintains | Outperform → Outperform | — | $44.65 | $44.46 | -0.4% | -1.6% | +0.7% | -2.0% | -2.9% | -2.9% |
| Aug 1 | RBC Capital | Maintains | Outperform → Outperform | — | $39.29 | $41.84 | +6.5% | +6.9% | +6.9% | +3.3% | +2.0% | +0.8% |
| May 9 | RBC Capital | Maintains | Outperform → Outperform | — | $42.68 | $42.65 | -0.1% | +2.2% | -0.2% | -1.3% | +3.5% | +5.3% |
| Mar 4 | UBS | Downgrade | Neutral → Sell | — | $45.53 | $44.13 | -3.1% | -2.6% | -5.7% | -5.8% | -1.8% | +1.6% |
| Feb 14 | Craig-Hallum | Downgrade | Buy → Hold | — | $66.77 | $46.27 | -30.7% | -32.2% | -34.1% | -37.5% | -30.2% | -25.9% |
| Feb 14 | JP Morgan | Downgrade | Neutral → Underweight | — | $66.77 | $46.27 | -30.7% | -32.2% | -34.1% | -37.5% | -30.2% | -25.9% |
| Feb 14 | RBC Capital | Maintains | Outperform → Outperform | — | $66.77 | $46.27 | -30.7% | -32.2% | -34.1% | -37.5% | -30.2% | -25.9% |
| Feb 14 | Raymond James | Downgrade | Strong Buy → Outperform | — | $66.77 | $46.27 | -30.7% | -32.2% | -34.1% | -37.5% | -30.2% | -25.9% |
| Feb 14 | William Blair | Downgrade | Outperform → Market Perform | — | $66.77 | $46.27 | -30.7% | -32.2% | -34.1% | -37.5% | -30.2% | -25.9% |
| Dec 21 | RBC Capital | Maintains | Outperform → Outperform | — | $70.96 | $72.26 | +1.8% | +4.0% | +4.3% | +6.1% | +6.3% | +5.7% |
| Dec 11 | Citigroup | Downgrade | Buy → Neutral | — | $66.02 | $65.79 | -0.3% | -0.4% | -0.7% | +6.9% | +9.5% | +7.6% |
| Nov 2 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $60.50 | $62.10 | +2.6% | +3.7% | +6.2% | +3.9% | +1.8% | -0.3% |
| Sep 19 | RBC Capital | Maintains | Outperform → Outperform | — | $75.04 | $75.11 | +0.1% | +1.0% | -2.1% | -4.3% | -4.5% | -4.6% |
| Aug 15 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $76.34 | $75.42 | -1.2% | -2.1% | -5.7% | -4.0% | -2.7% | +0.3% |
| Aug 9 | RBC Capital | Maintains | Outperform → Outperform | — | $82.26 | $79.80 | -3.0% | -7.3% | -5.9% | -5.3% | -7.2% | -9.2% |
| Aug 9 | JP Morgan | Maintains | Neutral → Neutral | — | $82.26 | $79.80 | -3.0% | -7.3% | -5.9% | -5.3% | -7.2% | -9.2% |
| May 4 | RBC Capital | Maintains | Outperform → Outperform | — | $93.23 | $92.70 | -0.6% | -6.5% | -5.0% | -5.3% | -7.7% | -6.5% |
| Feb 16 | RBC Capital | Maintains | Outperform → Outperform | — | $86.23 | $87.00 | +0.9% | +5.7% | +6.0% | +4.0% | +4.2% | +2.9% |
| Feb 16 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $86.23 | $87.00 | +0.9% | +5.7% | +6.0% | +4.0% | +4.2% | +2.9% |
| Dec 12 | Citigroup | Upgrade | Neutral → Buy | — | $92.30 | $95.00 | +2.9% | +5.6% | -11.1% | -8.5% | -6.7% | -10.5% |
| Nov 3 | JP Morgan | Maintains | Neutral → Neutral | — | $88.73 | $85.51 | -3.6% | -1.4% | +2.3% | -0.2% | -1.2% | -1.2% |
| Oct 14 | UBS | Upgrade | Sell → Neutral | — | $74.60 | $75.87 | +1.7% | +2.3% | +3.6% | +9.0% | +4.4% | +5.5% |
| May 6 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $102.66 | $103.64 | +1.0% | -4.3% | -10.2% | -10.9% | -13.2% | -9.9% |
| Feb 22 | Raymond James | Upgrade | Outperform → Strong Buy | — | $97.84 | $99.30 | +1.5% | +5.4% | +5.4% | +6.7% | +10.1% | +8.1% |
| Aug 6 | Raymond James | Maintains | Outperform → Outperform | — | $144.00 | $129.16 | -10.3% | -13.2% | -9.8% | -9.6% | -11.9% | -13.4% |
| Jun 28 | Raymond James | Maintains | Outperform → Outperform | — | $119.09 | $119.08 | -0.0% | +6.7% | +10.9% | +7.6% | +8.0% | +5.2% |
| Jun 17 | Craig-Hallum | Maintains | Buy → Buy | — | $112.03 | $111.13 | -0.8% | +0.7% | +1.6% | -0.2% | -0.8% | +0.7% |
| Jun 4 | JP Morgan | Maintains | Underweight → Underweight | — | $107.84 | $106.50 | -1.2% | -3.5% | +1.3% | +3.6% | +4.2% | +7.3% |
| May 7 | Raymond James | Maintains | Outperform → Outperform | — | $108.54 | $108.34 | -0.2% | +11.4% | +7.2% | +5.7% | +10.5% | +7.3% |
| Mar 11 | Craig-Hallum | Maintains | Buy → Buy | — | $130.01 | $134.07 | +3.1% | +3.3% | +4.8% | +8.5% | +6.8% | +9.8% |
| Mar 11 | Raymond James | Maintains | Outperform → Outperform | — | $130.01 | $134.07 | +3.1% | +3.3% | +4.8% | +8.5% | +6.8% | +9.8% |
| Feb 19 | Raymond James | Maintains | Outperform → Outperform | — | $210.10 | $193.07 | -8.1% | -13.1% | -22.2% | -20.3% | -18.1% | -20.9% |
| Jan 22 | Raymond James | Upgrade | Market Perform → Outperform | — | $218.49 | $222.59 | +1.9% | +6.9% | +9.2% | +3.5% | +2.6% | +4.0% |
| Jul 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $224.98 | $228.97 | +1.8% | +5.6% | +8.9% | +9.6% | +4.2% | +6.6% |
| May 12 | JP Morgan | Downgrade | Neutral → Underweight | — | $208.95 | $207.89 | -0.5% | -12.6% | -14.5% | -11.1% | -5.6% | -12.5% |
No insider trades available.
8-K
Unknown — 8-K Filing
Quidel issued preliminary financial estimates with explicit warnings about reliability, signaling uncertainty in near-term results and suggesting investors should await confirmed figures before making investment decisions.
Apr 15
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Without seeing the actual press release content in Exhibit 99.1, I cannot provide specific stock impact analysis, as the "transition described above" is not included in your summary.
Please share the full filing details or the press release text for accurate assessment.
Mar 24
8-K
QuidelOrtho Corporation -- 8-K Filing
I cannot provide a meaningful investment summary from this filing, as the document contains only technical XBRL metadata and schema references rather than substantive business information or corporate events.
Feb 13
8-K
QuidelOrtho Corporation -- 8-K Filing
QuidelOrtho is shifting its business model away from pandemic-dependent COVID diagnostics toward sustainable, diversified diagnostic products for more predictable future revenue.
Feb 11
8-K
QuidelOrtho Corporation -- 8-K Filing
QuidelOrtho Corporation filed an 8-K providing regulatory compliance documentation regarding its emerging growth company status and SEC filing requirements under Exchange Act provisions.
Feb 5
Data updated apr 26, 2026 9:28pm
· Source: massive.com